{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:56:14Z","timestamp":1792551374466,"version":"4.5.0"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100011542","name":"Center for Clinical and Translational Science, Mayo Clinic","doi-asserted-by":"publisher","award":["UL1TR002377"],"award-info":[{"award-number":["UL1TR002377"]}],"id":[{"id":"10.13039\/100011542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2025,10,8]]},"abstract":"ABSTRACT<\/jats:title>\n \n \n \n Achromobacter<\/jats:italic>\n species are Gram-negative bacilli that predominantly affect individuals with cystic fibrosis or those with immunocompromising conditions. Clinical and microbiologic data on\n Achromobacter<\/jats:italic>\n species are limited due to the rarity of these organisms and challenges with species-level identification. We conducted a 10-year retrospective analysis (1 January 2013 to 14 March 2023) of all bloodstream and non-bloodstream\n Achromobacter<\/jats:italic>\n isolates identified at three tertiary-care Mayo Clinic locations (Minnesota, Arizona, and Florida). Additionally, we examined clinical characteristics of adult patients with\n Achromobacter<\/jats:italic>\n bloodstream isolates. A total of 1,598\n Achromobacter<\/jats:italic>\n isolates, encompassing 1,545 non-bloodstream isolates and 53 bloodstream isolates, were identified. The most frequently identified species was\n Achromobacter xylosoxidans<\/jats:italic>\n , though species-level identification was not possible for many isolates. Among adult patients with\n Achromobacter<\/jats:italic>\n bloodstream infection, the mean age was 58.3 years (standard deviation \u00b1 16.7), 73.1% had a central venous catheter, and 59.6% were immunocompromised. All-cause mortality was 10.2% at 30 days and 18.4% at 90 days. Bloodstream isolates exhibited greater than 90% susceptibility to meropenem, piperacillin-tazobactam, and trimethoprim-sulfamethoxazole. The respiratory tract was the most common source of non-bloodstream isolates (57.5%). Non-bloodstream isolates showed high susceptibility to imipenem (94.6%), piperacillin-tazobactam (92.8%), trimethoprim-sulfamethoxazole (92.1%), and meropenem (87.5%) while demonstrating significant resistance to fluoroquinolones and aminoglycosides. Our findings support the use of piperacillin-tazobactam, carbapenems, or trimethoprim-sulfamethoxazole as initial therapy for\n Achromobacter<\/jats:italic>\n infections. Further research is needed to better define the clinical and microbiologic characteristics of\n Achromobacter<\/jats:italic>\n infections.\n <\/jats:p>\n \n IMPORTANCE<\/jats:title>\n \n Achromobacter<\/jats:italic>\n is a rare but important genus of bacteria that tends to cause infection in those with cystic fibrosis, recurrent healthcare exposures, and\/or an immunocompromising condition. There is limited data on the clinical profile of\n Achromobacter<\/jats:italic>\n infections as well as optimal antibiotic selection for affected patients. We conducted a retrospective study to improve understanding of the microbiologic and clinical characteristics of\n Achromobacter<\/jats:italic>\n . Our study consists of a 10-year survey of all\n Achromobacter<\/jats:italic>\n isolates processed by three Mayo Clinic tertiary-care centers in Minnesota, Florida, and Arizona from 2013 to 2023. We report multiple findings, including the clinical characteristics of patients with\n Achromobacter<\/jats:italic>\n bloodstream infection, the number of different\n Achromobacter<\/jats:italic>\n species identified, and the sources of isolates not obtained from blood cultures. We additionally present antimicrobial susceptibility results for\n Achromobacter<\/jats:italic>\n isolates. Our study provides guidance to clinicians treating\n Achromobacter<\/jats:italic>\n infections and, it is hoped, will facilitate ongoing study of\n Achromobacter<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>\n <\/jats:sec>","DOI":"10.1128\/jcm.00724-25","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T13:38:47Z","timestamp":1758289127000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Clinical and microbiologic features of\n Achromobacter<\/i>\n species: a 10-year, multicenter experience"],"prefix":"10.1128","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8837-1044","authenticated-orcid":true,"given":"David R.","family":"Bayless","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic College of Medicine & Science","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-5604","authenticated-orcid":true,"given":"Mitchell G.","family":"Dumais","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic College of Medicine & Science","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-232X","authenticated-orcid":true,"given":"Jack W.","family":"McHugh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic College of Medicine & Science","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9538-6214","authenticated-orcid":true,"given":"Nischal","family":"Ranganath","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic College of Medicine & Science","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Fida","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic College of Medicine & Science","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3507-6411","authenticated-orcid":true,"given":"Supavit","family":"Chesdachai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic College of Medicine & Science","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar M.","family":"Abu Saleh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic College of Medicine & Science","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02293-13"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.07.004"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.02422-21"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.10.002"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201406-288FR"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/gbe\/evx061"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.09.001"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01025-20"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02197-15"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000763"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201701-071OC"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25793"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2447"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4431-3"},{"key":"e_1_3_3_16_2","first-page":"268","article-title":"Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series","volume":"31","author":"P\u00e9rez Barrag\u00e1n E","year":"2018","unstructured":"P\u00e9rez Barrag\u00e1n E, Sandino P\u00e9rez J, Corbella L, Orellana MA, Fern\u00e1ndez-Ruiz M. 2018. Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series. Rev Esp Quimioter 31:268\u2013273.","journal-title":"Rev Esp Quimioter"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.3.569"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000798"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20604"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.12659\/msm.881796"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-003-0925-3"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.2.479"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2024.02.002"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.05.004"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2014.07.012"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202209_29664"},{"key":"e_1_3_3_27_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2025. Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0. https:\/\/www.eucast.org."},{"key":"e_1_3_3_28_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2024. EUCAST reading guide for broth microdilution. Version 5.0. EUCAST. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/MIC_testing\/Reading_guide_BMD_v_5.0_2024.pdf."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","unstructured":"Olbrecht M Echahidi F Pi\u00e9rard D Peeters C Vandamme P Wybo I Demuyser T. 2023. In vitro susceptibility of Achromobacter species isolated from cystic fibrosis patients: a 6-year survey Antimicrob Agents Chemother 67:e0037923. doi:10.1128\/aac.00379-23","DOI":"10.1128\/aac.00379-23"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00264-25"},{"key":"e_1_3_3_31_2","unstructured":"CLSI. 2025. Performance Standards for Antimicrobial Susceptibility Testing. 35th ed. CLSI supplement M100 Clinical and Laboratory Standards Institute"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1157010"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad100"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404991"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1054"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6348"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad605"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017730838"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-024-05017-0"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.03.031"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2020.105889"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00724-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00724-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T13:01:00Z","timestamp":1759928460000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.00724-25"}},"subtitle":[],"editor":[{"given":"Jennifer","family":"Dien Bard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,8]]}},"alternative-id":["10.1128\/jcm.00724-25"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00724-25","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"2025-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00724-25"}}